Whole brain radiation was “first used in 1954.” That means that millions of cancer survivors have received whole brain radiation since then. Dr. Paul Brown, professor of radiation oncology at the University of Texas MD Anderson Cancer Center, Houston is quoted as admitting that “The potential benefits of whole brain radiation therapy are far outweighed by the detriments of the therapy itself…”
It has taken conventional oncology over 60 years to determine that the “potential benefits” of whole brain radiation are “far outweighed” by the “detriments” aka collateral damage.
Don’t expect your oncologist to raise the subject of collateral damage aka side effects. Expect your oncologist to offer standard FDA approved cancer therapies. It is up to you to identify and prevent the side effects from these standard FDA approved therapies.
Cancer that spreads to the brain to cause metastases is a common problem in cancer management. The question for your oncologist for this or any aggressive cancer therapy is:
1) will this therapy help me live longer? If so, by how much (on average)
2) how will this therapy affect my quality of life?
Have you been diagnosed with cancer? Are you considering undergoing whole brain radiation?
For more information about your cancer and the pros and cons of therapies you may be considering, scroll down the page, post a question or comment and I will reply ASAP.
“While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn’t extend survival.
“The potential benefits of whole brain radiation therapy are far outweighed by the detriments of the therapy itself”…
Brain metastases is a common problem in cancer affecting an estimated 400,000 to 600,000 patients annually in the U.S. alone, some 200,000 of whom get whole brain radiation during the course of their disease. Lung cancer is the most common malignancy to spread to the brain, followed by breast cancer and melanoma…
Whole brain radiation was first used in 1954 and has long been a standard strategy for brain metastases…”